Myocarditis and pericarditis associated with SARS-CoV-2 vaccines

Together with colleagues across Europe we have recently published our work entitled “Myocarditis and pericarditis associated with SARS-CoV-2 vaccines: a population-based descriptive cohort and a nested self-controlled risk interval study using electronic health care data from four European countries” in Frontiers in Pharmacology.

In this multi-country study that used data from four countries, the researchers studied first myo-/pericarditis diagnosis after exposure to first and second dose of Pfizer, AstraZeneca, Moderna, and Janssen COVID-19 vaccines. The study followed the design of a population-based cohort study with nested self-controlled risk interval (SCRI). Individuals were followed from 01/01/2020 until end of data availability (31/12/2021 latest).

Over 35 million individuals (49·2% women, median age 39–49 years) were included, of which 57·4% received at least one COVID-19 vaccine dose. Baseline incidence of myocarditis was low. Myocarditis IRRs were elevated after vaccination in those aged < 30 years, after both Pfizer vaccine doses (IRR = 3·3, 95%CI 1·2-9.4; 7·8, 95%CI 2·6-23·5, respectively) and Moderna vaccine dose 2 (IRR = 6·1, 95%CI 1·1-33·5). An effect of AstraZeneca vaccine dose 2 could not be excluded (IRR = 2·42, 95%CI 0·96-6·07). Pericarditis was not associated with vaccination. Important to note is that the absolute incidence of myocarditis remains low.

Please read the full article to check more detailed methodology and results.

Share this article